Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,348 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Thiamine vs. Placebo on VO2 in Critical Illness

NCT01985685
View directory record Official record
Conditions
Critically Ill, Respiratory Failure
Interventions
Thiamine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 21, 2026, 7:26 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

NCT04138485
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
IgPro10, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

NCT02839876
View directory record Official record
Conditions
Osteoarthritis, Acetaminophen, Arthroplasty, Hip Replacement
Interventions
Intravenous acetaminophen, Oral acetaminophen
Drug
Lead sponsor
Duke University
Other
Eligibility
56 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

NCT02481674
View directory record Official record
Conditions
Huntington's Disease
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
21 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 3 Interventional

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

NCT05266001
View directory record Official record
Conditions
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Interventions
GM-CSF, Placebo
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Day to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of AV-001 in Healthy Subjects

NCT04737486
View directory record Official record
Conditions
Covid19-associated ARDS, Covid19, ARDS
Interventions
AV-001, Placebo
Drug · Other
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 21, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 21, 2026, 7:26 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

NCT00106184
View directory record Official record
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 21, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
40
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 4 Interventional

Oral vs IV Sedation for Cataract Surgery in Older Adults

NCT07154147
View directory record Official record
Conditions
Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions
Alprazolam, Midazolam
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

NCT01099449
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
Interventions
calcium gluconate, magnesium sulfate, placebo, oxaliplatin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
404
States / cities
Fairbanks, Alaska • Antioch, California • Fairfield, California + 278 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 21, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

NCT05547438
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
NTS-104 TRIS, Placebo
Drug
Lead sponsor
NeuroTrauma Sciences, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 7:26 AM EDT
Withdrawn Phase 1 Interventional

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

NCT05322616
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
JK07, Matching Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

NCT03302234
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Burbank, California • Monterey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 21, 2026, 7:26 AM EDT
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

NCT03446599
View directory record Official record
Conditions
Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions
Hydroxocobalamin, Methylene Blue, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

NCT02586233
View directory record Official record
Conditions
Acute Ischemic Stroke, Thrombotic Disease
Interventions
DS-1040b, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 21, 2026, 7:26 AM EDT